MBX-500, a Hybrid Antibiotic with In Vitro and In Vivo Efficacy against Toxigenic Clostridium difficile
Antimicrobial Agents and Chemotherapy, 08/20/2012
Butler MM et al. – Finally, MBX–500 was efficacious in a murine model of CDI, again demonstrating a fully protective effect and permitting near–normal weight gain in the treated animals. These selective anti–CDI features support the further development of MBX 500 for the treatment of CDI.